Cencora, Inc. $COR Stake Trimmed by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. cut its position in shares of Cencora, Inc. (NYSE:COR) by 4.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 19,016 shares of the company’s stock after selling 796 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $5,702,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Triglav Investments D.O.O. raised its holdings in shares of Cencora by 24.7% during the second quarter. Triglav Investments D.O.O. now owns 20,200 shares of the company’s stock valued at $6,057,000 after acquiring an additional 4,000 shares during the period. American Institute for Advanced Investment Management LLP grew its position in Cencora by 1.1% during the 2nd quarter. American Institute for Advanced Investment Management LLP now owns 14,787 shares of the company’s stock worth $4,434,000 after purchasing an additional 160 shares in the last quarter. Plato Investment Management Ltd raised its stake in Cencora by 12.3% during the 2nd quarter. Plato Investment Management Ltd now owns 2,066 shares of the company’s stock valued at $617,000 after purchasing an additional 227 shares during the period. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Cencora in the second quarter valued at $61,000. Finally, Hills Bank & Trust Co boosted its position in shares of Cencora by 4.7% in the second quarter. Hills Bank & Trust Co now owns 7,710 shares of the company’s stock worth $2,312,000 after buying an additional 344 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Down 1.1%

COR opened at $337.60 on Friday. The company has a market capitalization of $65.45 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $350.46. The business has a 50-day moving average of $308.09 and a 200-day moving average of $297.11.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. During the same quarter in the previous year, the business posted $3.34 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 22.63%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wells Fargo & Company upped their price target on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. UBS Group lifted their target price on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $329.55.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 in the last 90 days. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.